enGene Holdings Inc.
ENGN · NASDAQ
10/31/2025 | 10/31/2024 | 10/31/2023 | 10/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.11 | 0.00 | -90.86 |
| FCF Yield | -27.33% | -12.46% | -5.32% | -5.61% |
| EV / EBITDA | -3.08 | -4.75 | -4.21 | 1,175.72 |
| Quality | ||||
| ROIC | -61.74% | 20.94% | -31.68% | -1.40% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.88 | 0.25 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -104.70% | -96.34% | -41.23% | -9.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.16 | 2.84 | 0.76 | -1.17 |
| Interest Coverage | -41.14 | 22.26 | -5.26 | -1.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,795.91 | -1,594.47 | -2,411.09 | 0.00 |